
NCRx Pipeline Report Special Edition: Humira Biosimilar Update
The expiration of the Humira® (adalimumab) patent has been long and enthusiastically anticipated and is finally upon us in 2023. And, as we all have

The expiration of the Humira® (adalimumab) patent has been long and enthusiastically anticipated and is finally upon us in 2023. And, as we all have

National CooperativeRx continually monitors the pharmaceutical pipeline. The pharmacy market is dynamic and complex, and it’s important to understand how changes may impact your plan

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring

National CooperativeRx constantly monitors the pharmaceutical pipeline. As treatment options change, it’s important to know how those changes could impact your plan and which drugs bring